173 related articles for article (PubMed ID: 11801551)
21. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma.
Yamamoto H; Vinitketkumnuen A; Adachi Y; Taniguchi H; Hirata T; Miyamoto N; Nosho K; Imsumran A; Fujita M; Hosokawa M; Hinoda Y; Imai K
Carcinogenesis; 2004 Dec; 25(12):2353-60. PubMed ID: 15333466
[TBL] [Abstract][Full Text] [Related]
22. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.
Zeng ZS; Cohen AM; Zhang ZF; Stetler-Stevenson W; Guillem JG
Clin Cancer Res; 1995 Aug; 1(8):899-906. PubMed ID: 9816060
[TBL] [Abstract][Full Text] [Related]
23. Increased activity of matrix metalloproteinase 2 and 9 after hepatic radiofrequency ablation.
Frich L; Bjørnland K; Pettersen S; Clausen OP; Gladhaug IP
J Surg Res; 2006 Oct; 135(2):297-304. PubMed ID: 16934296
[TBL] [Abstract][Full Text] [Related]
24. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
25. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
26. Expression and activity levels of matrix metalloproteinase-7 and in situ localization of caseinolytic activity in colorectal cancer.
Keles D; Arslan B; Terzi C; Tekmen I; Dursun E; Altungoz O; Oktay G
Clin Biochem; 2014 Sep; 47(13-14):1265-71. PubMed ID: 24930385
[TBL] [Abstract][Full Text] [Related]
27. Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases.
Tzimas GN; Chevet E; Jenna S; Nguyên DT; Khatib AM; Marcus V; Zhang Y; Chrétien M; Seidah N; Metrakos P
BMC Cancer; 2005 Nov; 5():149. PubMed ID: 16293189
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma.
Wang WS; Chen PM; Wang HS; Liang WY; Su Y
Carcinogenesis; 2006 May; 27(5):1113-20. PubMed ID: 16474169
[TBL] [Abstract][Full Text] [Related]
29. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
30. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer.
Johnston SJ; Ridge SA; Cassidy J; McLeod HL
Clin Cancer Res; 1999 Sep; 5(9):2566-70. PubMed ID: 10499634
[TBL] [Abstract][Full Text] [Related]
31. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
[TBL] [Abstract][Full Text] [Related]
32. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma.
Ip YC; Cheung ST; Fan ST
Mol Carcinog; 2007 Mar; 46(3):225-30. PubMed ID: 17219425
[TBL] [Abstract][Full Text] [Related]
33. [Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue].
Ishibashi K; Sobajima J; Ishiguro T; Okada N; Miyazaki T; Yokoyama M; Ishida H
Gan To Kagaku Ryoho; 2009 Mar; 36(3):425-9. PubMed ID: 19295266
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.
Waas ET; Wobbes T; Lomme RM; DeGroot J; Ruers T; Hendriks T
Br J Surg; 2003 Dec; 90(12):1556-64. PubMed ID: 14648736
[TBL] [Abstract][Full Text] [Related]
35. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
36. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
37. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide.
Yonemura Y; Endo Y; Fujita H; Kimura K; Sugiyama K; Momiyama N; Shimada H; Sasaki T
J Exp Clin Cancer Res; 2001 Jun; 20(2):205-12. PubMed ID: 11484976
[TBL] [Abstract][Full Text] [Related]
39. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
[TBL] [Abstract][Full Text] [Related]
40. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
